Cargando…
Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
Targeted immunotherapy of solid cancers with chimeric antigen receptor (CAR) T cells and immunocytokines are attractive options in that they both rely on the specificity of tumor-targeted antibodies. Since carcinoembryonic antigen (CEA) expression in both colon and breast cancers is correlated with...
Autores principales: | Cha, Seung E., Kujawski, Maciej, J. Yazaki, Paul, Brown, Christine, Shively, John E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993151/ https://www.ncbi.nlm.nih.gov/pubmed/33796409 http://dx.doi.org/10.1080/2162402X.2021.1899469 |
Ejemplares similares
-
Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
por: Kujawski, Maciej, et al.
Publicado: (2020) -
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017) -
S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014) -
(89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
por: van Brummelen, Emilie M.J., et al.
Publicado: (2018) -
The site of binding of anti-CEA antibodies to tumour CEA in vivo: an immunocytochemical and autoradiographic approach.
por: Moshakis, V., et al.
Publicado: (1982)